Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption.
about
A new insight into hepatitis C vaccine developmentHepatitis C virus relies on lipoproteins for its life cycleHost restriction factors for hepatitis C virusHost-Targeting Agents to Prevent and Cure Hepatitis C Virus InfectionHepatitis C virus comes for dinner: How the hepatitis C virus interferes with autophagyImpact of lipids and lipoproteins on hepatitis C virus infection and virus neutralizationHuman immunodeficiency virus and heparan sulfate: from attachment to entry inhibitionBasic residues in hypervariable region 1 of hepatitis C virus envelope glycoprotein e2 contribute to virus entry.Association between Hepatitis C Virus and Very-Low-Density Lipoprotein (VLDL)/LDL Analyzed in Iodixanol Density GradientsViral and Cellular Determinants of the Hepatitis C Virus Envelope-Heparan Sulfate InteractionRole of the Low-Density Lipoprotein Receptor in Entry of Bovine Viral Diarrhea VirusSulfated Homologues of Heparin Inhibit Hepatitis C Virus Entry into Mammalian CellsBinding of liver derived, low density hepatitis C virus to human hepatoma cellsApolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptorPersistent growth of a human plasma-derived hepatitis C virus genotype 1b isolate in cell cultureA novel small molecule inhibitor of hepatitis C virus entryNovel small-molecule inhibitors of hepatitis C virus entry block viral spread and promote viral clearance in cell culturePromising candidates for the treatment of chronic hepatitis C.Recombinant hepatitis C virus-envelope protein 2 interactions with low-density lipoprotein/CD81 receptors.HCV infection of the transplanted liver: changing CD81 and HVR1 variants immediately after liver transplantation.Direct binding of the ligand PSG17 to CD9 requires a CD9 site essential for sperm-egg fusion.A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infectionHepatitis C virus entry: molecular mechanisms and targets for antiviral therapy.Human coronavirus NL63 utilizes heparan sulfate proteoglycans for attachment to target cellsRecombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.Proteoglycans act as cellular hepatitis delta virus attachment receptors.Functional characterization of nuclear localization and export signals in hepatitis C virus proteins and their role in the membranous web.Differential expression of candidate virus receptors in human T lymphocytes prone or resistant to infection with patient-derived hepatitis C virus.Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry.Hepatitis C virus therapies: current treatments, targets and future perspectives.Lipid metabolism and HCV infectionCharacterization of hepatitis C virus interaction with heparan sulfate proteoglycans.Excess body weight, liver steatosis, and early fibrosis progression due to hepatitis C recurrence after liver transplantationModeling hepatitis C virus infection using human induced pluripotent stem cells.Hepatitis C virus infection of human T lymphocytes is mediated by CD5.A Library of Infectious Hepatitis C Viruses with Engineered Mutations in the E2 Gene Reveals Growth-Adaptive Mutations That Modulate Interactions with Scavenger Receptor Class B Type I.Hepatitis C virus utilizes lipid droplet for production of infectious virus.MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cellsHepatitis C virus entry.Identification of transferrin receptor 1 as a hepatitis C virus entry factor
P2860
Q21296858-F8E1036A-315A-455D-99C9-54A3DF5F824DQ26766119-76650AB8-186F-469A-BF31-E95596889324Q26773258-B13495C9-C1D2-43AC-B934-BD822309D674Q26779128-864BB5A4-CFDE-46D3-A091-52D702B4A540Q26801207-E7431A00-4F56-4B71-AB0F-70A9EC57B7C2Q26864485-598CDFAA-2A5F-403E-8753-511CBC02FBBAQ27004059-D9705C7F-1203-4BD5-9405-9F985D6D530EQ27472768-EBD23957-CCCD-4878-98F6-6BC9961DA118Q27473044-2DC4174A-112D-4C8F-B622-1AF015CD3A73Q27477606-1A949F4C-6054-4B76-8FB5-C59CC4C3E3EEQ27477607-E82625C2-7321-4151-B1C7-A90A6210BDB2Q27478383-BE0A0AAE-4376-45F4-9916-82BBF7EC4AC3Q27486525-E73E0DD5-0E37-486B-9ABC-9497F0362453Q27490234-6A9F50F5-4171-484C-9484-C7C89581C1CAQ28473992-7FC6D297-0414-4151-9E8E-82DF0887822BQ28475468-36196292-CF82-4C8F-BD95-C00327D46DC0Q28482494-879944E1-D96C-417D-9BBA-DB420CBF957CQ30333233-573D2450-5678-4712-B2B0-B8F27DCCA271Q30375044-80E2E29B-E663-4987-8C7C-8164652686A8Q30438047-7A34BAC3-A028-411B-8243-C34DDF6F0BD5Q33763806-0915B85A-65B9-4BA9-BDA5-E51C992F939CQ34009510-EFF823B9-77D0-4954-AB80-390132308530Q34016463-EC8B58C7-6982-4902-944F-386161D81C14Q34594739-0D33F3AF-BFFC-4007-B3EB-46BF41355DCCQ34594986-DA6694EA-1244-4BEA-80A0-5FD025C9FEC7Q34625734-04591408-863D-45BA-8291-9F96269D0FF4Q34653969-A9956E6F-2F1A-49D3-9F1D-FAFBED7F30AAQ34692827-4E7D7F5F-56C3-40C3-844A-B2E0611FA77BQ34908895-E3D3AD02-00AD-4F6F-A2FC-1E73E9C09B53Q35147050-5B267941-B62F-4EC2-87C1-498160498E30Q35275932-512001EF-421C-41C2-8466-528AB6248197Q35488198-7E001E38-2E90-452E-8BF6-E3F61B933614Q35621603-AE368ED8-9139-4D7A-A456-5F8B6464DF03Q35787014-CCACF237-ACB2-4B6E-8201-96E55857EF63Q35826843-89041EB0-F85E-4D70-8375-A172DCC4261DQ36133495-99C8E381-268E-438D-97B0-32C3DD7EF73DQ36580492-7E2629F7-0EE2-460B-951D-34638D9E17E8Q36759971-BE995F6F-3F5F-437C-8BEF-702C307B55BBQ36946317-D80CB850-D996-432C-A7C1-DE013ACDD1F3Q36967731-0593B18E-3840-4123-A40F-1C71A04F3241
P2860
Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Cellular glycosaminoglycans an ...... hepatitis C virus adsorption.
@en
type
label
Cellular glycosaminoglycans an ...... hepatitis C virus adsorption.
@en
prefLabel
Cellular glycosaminoglycans an ...... hepatitis C virus adsorption.
@en
P2093
P2860
P356
P1476
Cellular glycosaminoglycans an ...... hepatitis C virus adsorption.
@en
P2093
Daniel Garin
Emmanuel Drouet
Hugues Lortat-Jacob
Jean-Marc Crance
Jean-Pierre Zarski
Josette Guimet
Raphaële Germi
Rob W H Ruigrok
P2860
P304
P356
10.1002/JMV.10196
P577
2002-10-01T00:00:00Z